Aptevo Therapeutics (NASDAQ:APVO) had its target price raised by Piper Jaffray Companies from $4.00 to $4.50 in a research note issued to investors on Monday, April 15th, The Fly reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. Piper Jaffray Companies’ price target would suggest a potential upside of 458.04% from the stock’s current price. Piper Jaffray Companies also issued estimates for Aptevo Therapeutics’ Q2 2019 earnings at ($0.28) EPS, FY2019 earnings at ($1.22) EPS, Q1 2020 earnings at ($0.26) EPS and FY2020 earnings at ($1.11) EPS.
Other equities analysts have also recently issued research reports about the company. ValuEngine raised Aptevo Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, April 5th. Zacks Investment Research raised Aptevo Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a report on Thursday, March 14th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $7.88.
Aptevo Therapeutics stock opened at $0.81 on Monday. The company has a quick ratio of 2.66, a current ratio of 2.76 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $34.63 million, a PE ratio of -0.34 and a beta of 2.64. Aptevo Therapeutics has a 1-year low of $0.67 and a 1-year high of $6.35.
A number of large investors have recently bought and sold shares of APVO. Dimensional Fund Advisors LP increased its stake in Aptevo Therapeutics by 5.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,425,567 shares of the biotechnology company’s stock worth $7,242,000 after buying an additional 73,911 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Aptevo Therapeutics by 11.1% in the third quarter. Renaissance Technologies LLC now owns 1,277,100 shares of the biotechnology company’s stock valued at $6,488,000 after purchasing an additional 127,700 shares in the last quarter. Acadian Asset Management LLC grew its position in shares of Aptevo Therapeutics by 4.8% in the fourth quarter. Acadian Asset Management LLC now owns 462,824 shares of the biotechnology company’s stock valued at $587,000 after purchasing an additional 21,059 shares in the last quarter. Clifford Swan Investment Counsel LLC purchased a new stake in shares of Aptevo Therapeutics in the fourth quarter valued at approximately $35,000. Finally, Deutsche Bank AG grew its position in shares of Aptevo Therapeutics by 251.7% in the fourth quarter. Deutsche Bank AG now owns 330,200 shares of the biotechnology company’s stock valued at $419,000 after purchasing an additional 236,300 shares in the last quarter. Institutional investors own 17.08% of the company’s stock.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.
Further Reading: Discount Rate
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.